Sorrento Therapeutics Net Income

Sorrento Therapeutics (SRNE) currently reports a net income of $-530M as of June 2023. That compares with $-530M in the prior-year period — down 1.7% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Sorrento Therapeutics's net income history and peer comparisons.

Sorrento Therapeutics's net income decreased from $-530M to $-530M — a 1.7% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sorrento Therapeutics's net income of $-530M is lower than the Healthcare sector average of $17B. That is roughly 103.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Sorrento Therapeutics reported $-530M in net income as of June 2023. That compares with $-530M in the prior-year period — down 1.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-530M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Sorrento Therapeutics, and consider following SRNE for alerts when major investors trade the stock.